Matthieu Ruffin

686 total citations · 1 hit paper
10 papers, 536 citations indexed

About

Matthieu Ruffin is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Matthieu Ruffin has authored 10 papers receiving a total of 536 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Surgery and 3 papers in Epidemiology. Recurrent topics in Matthieu Ruffin's work include Pituitary Gland Disorders and Treatments (10 papers), Growth Hormone and Insulin-like Growth Factors (8 papers) and Adrenal and Paraganglionic Tumors (6 papers). Matthieu Ruffin is often cited by papers focused on Pituitary Gland Disorders and Treatments (10 papers), Growth Hormone and Insulin-like Growth Factors (8 papers) and Adrenal and Paraganglionic Tumors (6 papers). Matthieu Ruffin collaborates with scholars based in Switzerland, United States and United Kingdom. Matthieu Ruffin's co-authors include Karina Hermosillo Reséndiz, Pamela U. Freda, Marcello D. Bronstein, Andrew J. Farrall, Mônica R. Gadelha, Maria Fleseriu, Chiung‐Chyi Shen, Annamaria Colao, Feng Gu and Mary N. Sheppard and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, European Journal of Endocrinology and The Journal of Clinical Pharmacology.

In The Last Decade

Matthieu Ruffin

10 papers receiving 528 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

2014 302 citations Annamaria Colao, Marcello D. Bronstein et al. The Journal of Clinical Endocrinology & Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthieu Ruffin Switzerland	8	499	225	193	43	37	10	536
Karina Hermosillo Reséndiz United States	9	587 1.2×	252 1.1×	270 1.4×	59 1.4×	41 1.1×	11	675
Vyacheslav Pronin Russia	5	318 0.6×	148 0.7×	112 0.6×	30 0.7×	33 0.9×	19	353
Muriel Cogne France	9	307 0.6×	103 0.5×	137 0.7×	33 0.8×	13 0.4×	16	355
Daniel Cuevas-Ramos Mexico	6	348 0.7×	168 0.7×	97 0.5×	48 1.1×	49 1.3×	7	387
U Schoenherr Switzerland	3	400 0.8×	183 0.8×	99 0.5×	30 0.7×	44 1.2×	5	447
Mascia Albizzi Italy	4	345 0.7×	149 0.7×	123 0.6×	23 0.5×	14 0.4×	5	370
M Barausse Italy	10	491 1.0×	203 0.9×	140 0.7×	33 0.8×	55 1.5×	11	511
Yixin Chen United States	4	283 0.6×	138 0.6×	96 0.5×	34 0.8×	25 0.7×	8	323
P. Chanson France	8	298 0.6×	107 0.5×	149 0.8×	16 0.4×	23 0.6×	17	350
Vivien Herman-Bonert United States	7	325 0.7×	127 0.6×	89 0.5×	35 0.8×	35 0.9×	7	362

Countries citing papers authored by Matthieu Ruffin

Since Specialization

Citations

This map shows the geographic impact of Matthieu Ruffin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthieu Ruffin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthieu Ruffin more than expected).

Fields of papers citing papers by Matthieu Ruffin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthieu Ruffin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthieu Ruffin. The network helps show where Matthieu Ruffin may publish in the future.

Co-authorship network of co-authors of Matthieu Ruffin

This figure shows the co-authorship network connecting the top 25 collaborators of Matthieu Ruffin. A scholar is included among the top collaborators of Matthieu Ruffin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthieu Ruffin. Matthieu Ruffin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Bronstein, Marcello D., Maria Fleseriu, Sebastian Neggers, et al.. (2016). Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocrine Disorders. 16(1). 16–16. 64 indexed citations

Sheppard, Michael C., Marcello D. Bronstein, Pamela U. Freda, et al.. (2014). Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 18(3). 385–394. 67 indexed citations

Colao, Annamaria, Marcello D. Bronstein, Pamela U. Freda, et al.. (2014). Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. The Journal of Clinical Endocrinology & Metabolism. 99(3). 791–799. 302 indexed citations breakdown →

Petersenn, Stephan, Andrew J. Farrall, Christophe De Block, et al.. (2013). Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary. 17(2). 132–140. 42 indexed citations

Freda, Pamela U., Maria Fleseriu, Annamaria Colao, et al.. (2013). Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study. Endocrine Abstracts. 7 indexed citations

Colao, Annamaria, Marcello D. Bronstein, Pamela U. Freda, et al.. (2012). Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study. 15th International & 14th European Congress of Endocrinology. 29. 12 indexed citations

Fleseriu, Maria, M C Sheppard, Marcello D. Bronstein, et al.. (2012). Pasireotide LAR vs octreotide LAR in patients with acromegaly: double-blind, crossover, extension period to a randomized, double-blind, multicenter, phase III study. 15th International & 14th European Congress of Endocrinology. 29. 3 indexed citations

Hu, Ke, et al.. (2012). Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. European Journal of Endocrinology. 166(5). 821–828. 25 indexed citations

Horsmans, Yves, Ke Hu, Matthieu Ruffin, et al.. (2012). Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study. The Journal of Clinical Pharmacology. 52(4). 552–558. 8 indexed citations

10.

Farrall, Andrew J., J. E. Glusman, Matthieu Ruffin, & Stephan Petersenn. (2008). Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from a phase II extension study. 16. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact